Are Curis Inc. (CRIS) stocks a prudent buy?

At the time of writing, Curis Inc. [CRIS] stock is trading at $0.79, up up 1.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRIS shares have lost -12.96% over the last week, with a monthly amount drifted -26.75%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 19, September 2022, Curis Announces Date for the 2nd Annual VISTA Symposium. In a post published today on Yahoo Finance, Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022.

From an analyst’s perspective:

Curis Inc. [NASDAQ: CRIS] stock has seen the most recent analyst activity on April 04, 2022, when Raymond James downgraded its rating to a Mkt Perform. Previously, Raymond James started tracking the stock with Outperform rating on October 13, 2021, and set its price target to $15. On March 25, 2021, B. Riley Securities initiated with a Buy rating and assigned a price target of $19 on the stock. Laidlaw started tracking the stock assigning a Buy rating and suggested a price target of $5 on July 29, 2020. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $4 as its price target on July 17, 2020. Guggenheim started tracking with a Buy rating for this stock on October 24, 2017, and assigned it a price target of $7. In a note dated March 02, 2016, Sun Trust Rbsn Humphrey initiated an Buy rating and iterated a target price of $3 on this stock.

For the past year, the stock price of Curis Inc. fluctuated between $0.70 and $8.50. Currently, Wall Street analysts expect the stock to reach $12.00 within the next 12 months. Curis Inc. [NASDAQ: CRIS] shares were valued at $0.79 at the most recent close of the market. An investor can expect a potential return of 1418.99% based on the average price forecast.

Analyzing the CRIS fundamentals

According to Curis Inc. [NASDAQ:CRIS], the company’s sales were 2.39 billion in the recent quarter, which represents an 4.30% jump. Gross Margin for this corporation currently stands at +85.74% with Operating Margin at -395.01%, Pretax Margin comes in at -426.67%, and Net Margin reading is -426.67%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7758 points at the first support level, and at 0.7604 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8082, and for the 2nd resistance point, it is at 0.8252.

Curis Inc. [CRIS] reported earnings per share of -$0.18 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $-0.02 and a surprise factor of -12.50%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.15 per share as compared to estimates of -$0.13 per share, a difference of $-0.02 representing a surprise of -15.40%.

Ratios To Look Out For

It is important to note that Curis Inc. [NASDAQ:CRIS] has a current ratio of 9.30. Further, the Quick Ratio stands at 9.11, while the Cash Ratio is 8.62. Considering the valuation of this stock, the price to sales ratio is 40.93, the price to book ratio is 4.81.

Transactions by insiders

Insider trading, which has resulted in 0 insider purchases of 0 shares and 0 insider sales of 0 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Dentzer James E, President & CEO, that happened on Jan 31 when 3094.0 shares were sold. President & CEO, Dentzer James E completed a deal on Jan 27 to sell 2406.0 shares.